(Q46898723)

English

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life

scientific article published in July 1996

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

quality of life

1 reference

based on heuristic

inferred from title

author name string

Crucitt MA

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Hyman W

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Grote T

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Tester W

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Madajewicz S

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Yee S

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Wentz A

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Griffin D

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Parasuraman TV

9

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Bryson J

10

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

publication date

1 July 1996

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

18

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

778-788

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980226-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980226-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980226-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980226-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980226-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980226-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life consequences of chemotherapy-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980226-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980226-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Advances in anti-emetic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980226-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(96)80226-8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/8879903

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46898723&oldid=2136981994"